Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002312 · ClinicalTrials.gov registry record · NA
The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine
A NA study, sponsored by Pharmacia and Upjohn.
- Completed
- Registry status
- NA
- Development phase
NCT00002312: Completed NA study, sponsored by Pharmacia and Upjohn.
NCT00002312 is a NA study that has completed, run by Pharmacia and Upjohn. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002312, a NA study, has completed, sponsored by Pharmacia and Upjohn.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To evaluate the pharmacokinetics, safety, and tolerance of delavirdine mesylate ( U-90152 ) after multiple doses given orally to asymptomatic HIV-1 positive patients who are maintained on a stable dose of zidovudine ( AZT ). To investigate the optimum dose regimen of U-90152 that gives average trough concentrations \> 1 micromolar in combination with standard AZT therapy, and to examine drug interactions between the two drugs. To establish the MTD of U-90152 in HIV-1 positive patients on stable AZT therapy. To investigate comparative pharmacokinetics between HIV-1 positive men and women.
Interventions
- DRUG Zidovudine
- DRUG Delavirdine mesylate
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002312
The ClinicalTrials.gov registry entry for NCT00002312 describes a study currently listed as completed, categorized as NA. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Pharmacia and Upjohn, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zidovudine is the first listed.
NCT00002312 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002312 about?
NCT00002312 is a clinical study titled "The Safety and Effectiveness of U-90152 in HIV-1 Infected Patients Who Take Zidovudine". To evaluate the pharmacokinetics, safety, and tolerance of delavirdine mesylate ( U-90152 ) after multiple doses given orally to asymptomatic HIV-1 positive patients who are maintained on a stable dose of zidovudine ( AZT ). To investigate the optimum dose regimen of U-90152 that gives average troug...
What is the current status of trial NCT00002312?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002312?
The interventions under investigation include: Zidovudine (DRUG), Delavirdine mesylate (DRUG).
Who is sponsoring clinical trial NCT00002312?
This trial is sponsored by Pharmacia and Upjohn, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.